A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Inclusion criteria

• . Patients with ≥1 International Classification of Diseases Clinical Modification, 10th revision (ICD-10-CM) diagnosis code for GEP-NET between 01 January 2018 and 31 December 2025. The date of the first such claim will be defined as the diagnosis date.
• . Initiation of first-line (1L) systemic therapy (i.e., somatostatin analogs \[SSAs\], targeted therapy, peptide receptor radionuclide therapy \[PRRT\], chemotherapy) indicated for GEP-NET on or after the date of diagnosis. The date of treatment initiation will be defined as the index date.
• . Patients ≥18 years of age on the index date
• . Patients with ≥12 months (360 days) of continuous data availability (proxy for continuous health plan enrollment) prior to the index date, defined as:
• . ≥1 medical and pharmacy claim \>12 months prior to the index date; AND
• . ≥1 medical and pharmacy claim within the first 6 months of the 12-month period prior to the index date; AND
• . ≥1 medical and pharmacy claim during the last 6 months of the 12-month period prior to the index date; AND
• . Patients with ≥1 month (30 days) of continuous data availability (proxy for continuous health plan enrollment) following the index date, defined as:

Exclusion criteria